|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM335794009 |
| 003 |
DE-627 |
| 005 |
20231225230654.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202106350
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1119.xml
|
| 035 |
|
|
|a (DE-627)NLM335794009
|
| 035 |
|
|
|a (NLM)35044699
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Yong, Seok-Beom
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Dual-Targeted Lipid Nanotherapeutic Boost for Chemo-Immunotherapy of Cancer
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 04.04.2022
|
| 500 |
|
|
|a Date Revised 05.04.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2022 The Authors. Advanced Materials published by Wiley-VCH GmbH.
|
| 520 |
|
|
|a Chemo-immunotherapy is a combination of "standard-of-care" chemotherapy with immunotherapy and it is considered the most advanced therapeutic modality for various types of cancers. However, many cancer patients still poorly respond to current regimen of chemo-immunotherapy and suggest nanotherapeutics as a boosting agent. Recently, heme oxygenase-1 (HO1) is shown to act as an immunotherapeutic molecule in tumor myeloid cells, in addition to general chemoresistance function in cancer cells suggesting that HO1-targeted therapeutics can become a novel, optimal strategy for boosting chemo-immunotherapy in the clinic. Currently the available HO1-inhibitors demonstrate serious adverse effects in clinical use. Herein, tumor myeloid cell- and cancer cell-dual targeted HO1-inhibiting lipid nanotherapeutic boost (T-iLNTB) is developed using RNAi-loaded lipid nanoparticles. T-iLNTB-mediated HO1-inhibition sensitizes cancer cells to "standard-of-care" chemotherapeutics by increasing immunogenic cell death, and directly reprograms tumor myeloid cells with distinguished phenotype. Furthermore, tumor myeloid cell reprogramming by T-iLNTB induces CD8+ cytotoxic T cell recruitment, which drives "Cold-to-Hot" transition and correlates with improved responsiveness to immune checkpoint inhibitor in combination therapy. Finally, ex vivo study proves that HO1-inhibition directly affects tumor macrophage differentiation. This study demonstrates the potential of T-iLNTB as a novel therapeutic modality for boosting chemo-immunotherapy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a HO1-targeted nanotherapeutics
|
| 650 |
|
4 |
|a cancer-targeted therapy
|
| 650 |
|
4 |
|a chemo-immunotherapy
|
| 650 |
|
4 |
|a ionizable lipid nanoparticle
|
| 650 |
|
4 |
|a targeted lipid nanoparticle
|
| 650 |
|
7 |
|a Lipid Nanoparticles
|2 NLM
|
| 650 |
|
7 |
|a Lipids
|2 NLM
|
| 650 |
|
7 |
|a Liposomes
|2 NLM
|
| 700 |
1 |
|
|a Ramishetti, Srinivas
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Goldsmith, Meir
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Diesendruck, Yael
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hazan-Halevy, Inbal
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chatterjee, Sushmita
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Somu Naidu, Gonna
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ezra, Assaf
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Peer, Dan
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 34(2022), 13 vom: 15. Apr., Seite e2106350
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:34
|g year:2022
|g number:13
|g day:15
|g month:04
|g pages:e2106350
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202106350
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 34
|j 2022
|e 13
|b 15
|c 04
|h e2106350
|